Immunoglobulin E specific for Phleum pratense allergens (Phl p-specific IgE)

Immunoglobulin E (IgE) antibodies specific for Phleum pratense (Timothy grass) allergens are the primary drivers of Type I hypersensitivity reactions in individuals sensitized to grass pollen. These antibodies recognize specific protein components of the pollen, most notably the major allergens Phl p 1 and Phl p 5 (WHO/IUIS Allergen Nomenclature, 2024). Upon exposure, these IgE molecules, which are typically bound to the high-affinity FcεRI receptors on mast cells and basophils, become cross-linked by the allergens. This cross-linking triggers the degranulation of these cells, releasing potent inflammatory mediators such as histamine and cysteinyl leukotrienes that cause the symptoms of allergic rhinitis and asthma (Janeway's Immunobiology, 9th edition). Therapeutic strategies targeting this pathway include the use of anti-IgE monoclonal antibodies like Omalizumab, which reduce the levels of circulating free IgE, and allergen-specific immunotherapy (AIT), which aims to shift the immune response from a Th2-mediated IgE production toward a Th1/Treg-mediated IgG4 production (EAACI Guidelines on Allergen Immunotherapy, 2018). Furthermore, the measurement of these specific IgE levels in the blood is a standard diagnostic tool for identifying grass pollen allergy. Reducing the activity or concentration of these antibodies is a central goal in managing severe allergic conditions.

Other names

Timothy grass-specific IgEAnti-Phleum pratense IgEsIgE to Phl pGrass pollen-specific IgE

Anti-IgE monoclonal antibodies bind to the Fc region of free IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils (National Center for Biotechnology Information, 2023). Allergen-specific immunotherapy (AIT) involves the administration of standardized allergen extracts to induce immunological tolerance, characterized by a decrease in allergen-specific IgE and an increase in protective IgG4 antibodies (EAACI Guidelines, 2018).